Skip to content

Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03068208
Enrollment
15
Registered
2017-03-01
Start date
2022-05-01
Completion date
2023-06-30
Last updated
2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen Amyloidosis

Keywords

Methylene blue, photodynamic therapy, primary cutaneous localized amyloidosis, lichen amyloidosis

Brief summary

Efficacy of Methylene blue mediated Photodynamic therapy for primary localized cutaneous amyloidosis treatment in Asians, pilot study.

Interventions

The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients, aged \> 18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathological findings.

Exclusion criteria

* Those with systemic disease associated cutaneous amyloidosis * Pregnancy or lactating woman * Those who are allergic to urea, olive oil * Those who are photosensitive to ultraviolet radiation * Those who had been previously treated with any of which -medications, radiation, laser within 3 months and 1 month for topical therapy

Design outcomes

Primary

MeasureTime frameDescription
Roughness evaluation by using visioscanChange from baseline roughness at every 2 weeks up to 16 weeksThe improvement of roughness during the treatment

Countries

Thailand

Contacts

PRINCIPAL_INVESTIGATOREinapak Amnarttrakul, M.D.

Chulalongkorn University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026